Monaco Asset Management SAM Makes New $3.46 Million Investment in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Key Points

• Monaco Asset Management SAM acquired 225,000 shares of Teva Pharmaceutical Industries, valued at approximately $3.46 million, making it the fund's 15th biggest holding.
• Several institutional investors significantly increased their stakes in Teva, with Harel Insurance boosting its ownership by 197,885%, now holding over 22 million shares.
• Analysts have issued a range of ratings for Teva, with Goldman Sachs and others setting target prices between $22.00 and $25.00, indicating a positive outlook for the company's stock.

Monaco Asset Management SAM bought a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 225,000 shares of the company's stock, valued at approximately $3,458,000. Teva Pharmaceutical Industries accounts for about 0.7% of Monaco Asset Management SAM's portfolio, making the stock its 15th largest position.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. XTX Topco Ltd bought a new stake in Teva Pharmaceutical Industries during the 1st quarter worth approximately $2,460,000. Banque Cantonale Vaudoise purchased a new position in Teva Pharmaceutical Industries in the first quarter worth $74,000. AGP Franklin LLC grew its position in Teva Pharmaceutical Industries by 932.2% in the first quarter. AGP Franklin LLC now owns 124,468 shares of the company's stock worth $1,913,000 after acquiring an additional 112,410 shares in the last quarter. TCW Group Inc. grew its position in Teva Pharmaceutical Industries by 23.9% in the first quarter. TCW Group Inc. now owns 135,202 shares of the company's stock worth $2,078,000 after acquiring an additional 26,105 shares in the last quarter. Finally, LPL Financial LLC grew its position in Teva Pharmaceutical Industries by 5.5% in the first quarter. LPL Financial LLC now owns 213,280 shares of the company's stock worth $3,278,000 after acquiring an additional 11,029 shares in the last quarter. Institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Stock Down 0.5%

NYSE TEVA traded down $0.07 during trading hours on Friday, reaching $15.38. 14,134,278 shares of the company's stock traded hands, compared to its average volume of 12,253,167. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $22.80. The firm has a market cap of $17.64 billion, a PE ratio of -96.13, a PEG ratio of 0.99 and a beta of 0.60. The firm has a 50-day simple moving average of $16.89 and a 200 day simple moving average of $16.67. The company has a debt-to-equity ratio of 2.59, a current ratio of 1.03 and a quick ratio of 0.74.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 47.68%. The company had revenue of $4.18 billion during the quarter, compared to analysts' expectations of $4.34 billion. During the same period last year, the company posted $0.61 EPS. Teva Pharmaceutical Industries's revenue was up .3% on a year-over-year basis. Sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on TEVA shares. Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research report on Monday, April 28th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. UBS Group cut their target price on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a research report on Thursday, June 26th. The Goldman Sachs Group started coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, June 6th. They issued a "buy" rating and a $24.00 target price for the company. Finally, Bank of America upped their target price on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $24.71.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the completion of the transaction, the executive vice president directly owned 9,989 shares of the company's stock, valued at approximately $170,012.78. The trade was a 38.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.49% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.